2LB Stock Overview A commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Iovance Biotherapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Iovance Biotherapeutics Historical stock prices Current Share Price US$5.99 52 Week High US$16.85 52 Week Low US$5.57 Beta 0.57 1 Month Change -19.22% 3 Month Change -42.11% 1 Year Change -18.62% 3 Year Change -56.90% 5 Year Change -72.03% Change since IPO -52.28%
Recent News & Updates
Forecast to breakeven in 2027 Jan 01
Iovance Biotherapeutics, Inc. Announces the Promotion of Raj Puri to Chief Regulatory Officer Nov 27
Third quarter 2024 earnings released: US$0.28 loss per share (vs US$0.46 loss in 3Q 2023) Nov 08
Iovance Biotherapeutics, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Nov 01
New minor risk - Profitability Aug 10
Forecast to breakeven in 2025 Aug 10 See more updates
Forecast to breakeven in 2027 Jan 01
Iovance Biotherapeutics, Inc. Announces the Promotion of Raj Puri to Chief Regulatory Officer Nov 27
Third quarter 2024 earnings released: US$0.28 loss per share (vs US$0.46 loss in 3Q 2023) Nov 08
Iovance Biotherapeutics, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Nov 01
New minor risk - Profitability Aug 10
Forecast to breakeven in 2025 Aug 10
Iovance Biotherapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Jul 30
New major risk - Share price stability Jul 29 Iovance Biotherapeutics, Inc.(NasdaqGM:IOVA) dropped from Russell 3000 Value Index
Iovance Biotherapeutics, Inc. Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced Melanoma Jun 28
Iovance Biotherapeutics, Inc. Elects Frederick G. Vogt as Director Jun 13
No longer forecast to breakeven Jun 06
New minor risk - Financial position May 10
Iovance Biotherapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024 May 03
Iovance Biotherapeutics, Inc., Annual General Meeting, Jun 11, 2024 May 01 Iovance Biotherapeutics, Inc. Agrees to A Proposed Settlement Apr 04
Iovance Biotherapeutics Announces Fda Has Lifted Clinical Hold on the Iov-Lun-202 Registrational Trial in Non-Small Cell Lung Cancer Mar 05
New minor risk - Profitability Mar 03
Iovance Biotherapeutics, Inc. to Report Q4, 2023 Results on Feb 28, 2024 Feb 23 Iovance Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $210.5781 million. Feb 21
Iovance Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $210.5781 million. Feb 20
Iovance Biotherapeutics, Inc.’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma Feb 19
New minor risk - Profitability Feb 10
Iovance Biotherapeutics, Inc. Announces Clinical Program Update for LN-145 in Non-Small Cell Lung Cancer Dec 27
Iovance Biotherapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023 Nov 01
New major risk - Share price stability Oct 25
New major risk - Financial position Sep 25
Independent Director recently bought €25m worth of stock Sep 18
Iovance Biotherapeutics, Inc. Announces U.S. Food and Drug Administration Updates Sep 16
New minor risk - Financial position Aug 09
Iovance Biotherapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023 Jul 25 Iovance Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $150 million. Jul 12
Iovance Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $150 million.
Iovance Biotherapeutics Announces First Patient Randomized in Phase 3 TILVANCE-301 Trial in Frontline Advanced Melanoma Jun 16
Iovance Biotherapeutics, Inc. Announces U.S. Food and Drug Administration Accepts the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma May 31
Insufficient new directors May 01
Iovance Biotherapeutics, Inc. (NasdaqGM:IOVA) entered into a definitive agreement to acquire Worldwide rights of Proleukin of Clinigen Limited fo Jan 24
Independent Director recently bought €58k worth of stock Dec 23
Independent Director recently bought €62m worth of stock Dec 10
Independent Director recently bought €60k worth of stock Nov 30
Iovance Biotherapeutics, Inc. Provides Update on Biologics License Application Submission for Lifileucel in Advanced Melanoma Nov 19
Iovance Biotherapeutics, Inc. Announces Updated Clinical Data for Lifileucel in Advanced Melanoma At Society for Immunotherapy of Cancer (Sitc) Annual Meeting Nov 11
Iovance Biotherapeutics, Inc. Announces Updated Clinical Data for Lifileucel in Advanced Melanoma At Society for Immunotherapy of Cancer (SITC) Annual Meeting Nov 08
Iovance Biotherapeutics, Inc. to Report Q3, 2022 Results on Nov 03, 2022 Oct 25
Iovance Biotherapeutics, Inc. Announces First Patient Dosed with PD-1 Inactivated Tumor Infiltrating Lymphocyte Therapy Oct 11
Iovance Biotherapeutics Initiates Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma Aug 26
Iovance Biotherapeutics, Inc.(NasdaqGM:IOVA) dropped from Russell 1000 Dynamic Index Jun 26
Iovance Biotherapeutics, Inc. Appoints Wendy L. Dixon to Board of Directors Jun 14
Independent Director recently bought €6.2m worth of stock Jun 05
Iovance Biotherapeutics Announces Positive Clinical Data for Lifileucel in Advanced Melanoma May 27
Iovance Biotherapeutics, Inc. Announces Regulatory and Clinical Updates for Lifileucel in Melanoma Apr 06
No longer forecast to breakeven Feb 25
Iovance Biotherapeutics, Inc. to Report Q4, 2021 Results on Feb 24, 2022 Feb 12
Iovance Biotherapeutics, Inc. Initiates Clinical Supply of Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy Manufactured At Iovance Cell Therapy Center (iCTC) Sep 24
Iovance Biotherapeutics Announces Clinical Data for LN-145 in Non-Small Cell Lung Cancer Jun 30
Iovance Biotherapeutics, Inc. Announces Clinical Data for Lifileucel in Combination with Pembrolizumab in Advanced Melanoma at ASCO 2021 Annual Meeting Jun 05
Iovance Biotherapeutics Announces Clinical Data Updates for Lifileucel in Advanced Melanoma at Upcoming ASCO 2021 Annual Meeting May 21
Iovance Biotherapeutics, Inc. Provides Regulatory Update for Lifileucel Potency Assays May 19
Iovance Biotherapeutics, Inc. Appoints Igor Bilinsky as Chief Operating Officer Mar 16
Iovance Biotherapeutics, Inc. Announces Board Changes Mar 13
New 90-day low: €29.83 Feb 28
Iovance Biotherapeutics, Inc. to Report Q4, 2020 Results on Feb 25, 2021 Feb 19
Iovance Biotherapeutics, Inc. Enters into a Lease Agreement with ARE-San Francisco No. 63, LLC Feb 10
New 90-day high: €42.20 Jan 11
New 90-day high: €41.84 Dec 23
Iovance Biotherapeutics Appoints Jean-Marc Bellemin as Chief Financial Officer Dec 15
New 90-day high: €35.36 Dec 08
Iovance Biotherapeutics, Inc. Presents Clinical Data in Head and Neck Cancer At Society for Immunotherapy of Cancer (SITC) Annual Meeting Nov 10
New 90-day high: €33.85 Nov 06
Iovance Biotherapeutics, Inc. to Report Q3, 2020 Results on Nov 05, 2020 Oct 31
New 90-day high: €32.19 Oct 17
Iovance Biotherapeutics, Inc. Announces That Copy of an Abstract Submitted At Society for Immunotherapy in Cancer Annual Meeting Published by SITC Oct 16
Iovance Biotherapeutics Provides Update for Lifileucel in Metastatic Melanoma Oct 06 Iovance Biotherapeutics, Inc. Announces First Patient Dosed in Cohort 4 of Pivotal InnovaTIL-01 Study of Lifileucel in Metastatic Melanoma
New 90-day high - €28.48 Sep 03
New 90-day low - €23.78 Jul 24
Iovance Biotherapeutics, Inc. to Report Q2, 2020 Results on Aug 06, 2020 Jul 24
Iovance Biotherapeutics, Inc.(NasdaqGM:IOVA) dropped from Russell 2000 Index Jul 02 Shareholder Returns 2LB DE Biotechs DE Market 7D 0.8% 1.0% 1.9% 1Y -18.6% -4.3% 15.1%
See full shareholder returns
Return vs Market: 2LB underperformed the German Market which returned 15.1% over the past year.
Price Volatility Is 2LB's price volatile compared to industry and market? 2LB volatility 2LB Average Weekly Movement 11.3% Biotechs Industry Average Movement 6.1% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 2LB's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 2LB's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers.
Show more Iovance Biotherapeutics, Inc. Fundamentals Summary How do Iovance Biotherapeutics's earnings and revenue compare to its market cap? 2LB fundamental statistics Market cap €1.72b Earnings (TTM ) -€395.52m Revenue (TTM ) €87.65m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 2LB income statement (TTM ) Revenue US$90.86m Cost of Revenue US$82.82m Gross Profit US$8.04m Other Expenses US$418.04m Earnings -US$410.00m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.35 Gross Margin 8.85% Net Profit Margin -451.25% Debt/Equity Ratio 0.1%
How did 2LB perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/02 07:57 End of Day Share Price 2025/01/31 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Iovance Biotherapeutics, Inc. is covered by 25 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Colleen Kusy Baird Madhu Kumar Baird Peter Lawson Barclays
Show 22 more analysts 
